Tubulin binding potentially clears up Bortezomib and Carfilzomib differential neurotoxic effect
Abstract Proteasome inhibitors (PIs) represent the gold standard in the treatment of multiple myeloma. Among PIs, Bortezomib (BTZ) is frequently used as first line therapy, but peripheral neuropathy (PN), occurring approximately in 50% of patients, impairs their life, representing a dose-limiting to...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Nature Portfolio
2021
|
| Subjects: | |
| Online Access: | https://doaj.org/article/5bb52f7cbfd047d0957809e366036543 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|